Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy

Li Yu,Lyudmila Bazhenova,Kathryn Gold,Lisa Tran,Van Hilburn,Peter Vu,Sandip Pravin Patel

DOI: https://doi.org/10.21037/tlcr-21-665

2022-03-01

Translational Lung Cancer Research

Abstract:Background: Small cell lung cancer (SCLC) transformation is one of the mechanisms of drug resistance to tyrosine kinase inhibitors (TKIs) in advanced epidermal growth factor receptor (<i>EGFR</i>)-mutated non-small cell lung cancer (NSCLC) and represents an increasingly recognized clinical dilemma.Methods: We performed a retrospective review of 964 cases at the University of California, San Diego of patients with <i>EGFR</i> sensitizing mutations. Nine patients had a biopsy-confirmed small cell transformation. The unique gene alterations and clinicopathologic features were collected and analyzed.Results: Nine cases (9/964, 0.9%) were identified, all with stage IV adenocarcinoma (ADC) at diagnosis, 7 were poorly differentiated, and 7 had an <i>EGFR</i> exon 19 deletion. All nine patients had tumor protein p53 (<i>TP53</i>) mutation. Among seven cases that had next-generation sequencing (NGS), 5 harbored retinoblastoma 1 (<i>RB1</i>) loss. WNK lysine deficient protein kinase 1 (<i>WNK1</i>) mutation was found in two patients that had longer survival. The median time from the initial diagnosis to transformation was 22.7 months (IQR: 15.1-25.1). After small cell transformation on <i>EGFR</i> inhibition, all patients were treated with etoposide/platinum, conferring a median progression-free survival (PFS) of 3.2 months (IQR, 2.2-6.5 months) and post-chemotherapy survival of 8.6 months (IQR, 4.0-19.0 months). Six patients, as they retained the initial <i>EGFR</i> mutations, resumed (did so after terminating chemotherapy)/continued (did so concomitantly with chemotherapy) TKIs with a median duration of 13.8 months (IQR, 3.8-27.7 months). Two patients received immunotherapy but had no benefit.Conclusions: In our series, most patients with small cell transformation had poorly differentiated adenocarcinomas at baseline. <i>RB1</i> loss was not universal in transformed patients in this series, though <i>TP53</i> mutation was present in all tumor samples. <i>WNK1</i> mutation may be a new resistance mechanism to TKIs that may be associated with improved survival.

oncology,respiratory system